DRW Securities’s Aquestive Therapeutics AQST Stock Holding History

DRW Securities’s Portfolio AQST Stock Details AQST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-17,128	Closed	-$111K	–	1267
2025 Q4	$111K	Buy	+17,128	New	+$107K	﹤0.01%	1056

Other funds holding AQST

BCM

Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

DRW Securities's AQST Position: Q1 2026 in Review

DRW Securities sold out of Aquestive Therapeutics (AQST) in Q1 2026, closing a stake of 17,128 shares — an estimated $111K sold.

DRW Securities first reported a position in AQST in Q4 2025 and held it in 1 quarter. The position peaked at $111K in Q4 2025. 179 funds tracked by Wall St. Rank hold AQST as of Q1 2026.

DRW Securities reported no remaining Aquestive Therapeutics position as of Q1 2026 after selling out during the quarter.
DRW Securities sold 17,128 Aquestive Therapeutics shares in Q1 2026, an estimated $111K.
DRW Securities first reported a position in Aquestive Therapeutics in Q4 2025 and held it in 1 quarter.
DRW Securities's Aquestive Therapeutics position peaked at $111K in Q4 2025.
179 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q1 2026.

Based on DRW Securities's 13F filing for Q1 2026, filed 13 May 2026.